key: cord-1050470-08rso4sq
authors: Cheung, Amanda; Kwo, Paul
title: Viral Hepatitis Other Than A, B, and C: Evaluation and Management
date: 2020-04-13
journal: Clin Liver Dis
DOI: 10.1016/j.cld.2020.04.008
sha: 02c4d68308bd1b9b108f544de3337c9a6320309c
doc_id: 1050470
cord_uid: 08rso4sq

Viral hepatitis causes a wide spectrum of presentations from a benign form with minimal or no symptoms to acute liver failure or death. Hepatitis D coinfection and superinfection have distinct clinical courses with the latter more likely leading to chronic infection. Management of chronic HDV is individualized due to the paucity of treatment options and significant side effect profile of currently available treatments. Hepatitis E was once thought to be an infection limited to developing nations with high endemicity, but sporadic cases due to contaminated meats is becoming increasingly prevalent in immunocompromised hosts. Human herpes viruses are an important cause of disease also in the immunocompromised individual.

The term viral hepatitis refers to liver inflammation that occurs due to a viral infection. There are five hepatotropic viruses, hepatitis A, B, C, D, and E, that selectively infect the liver. Acute hepatitis due to these viruses may resolve without intervention or in some instances develop into chronic infections. Nonhepatotropic viruses target different organs in the body but are also known to cause hepatitis, albeit these infections are typically mild in the immunocompetent host. The significance of nonhepatotropic viruses are most notable in the immunocompromised host, particularly in transplant recipients.

Hepatitis D, also called delta virus (HDV), was first described in 1977 in a group of hepatitis B virus (HBV) infected patients who were found to have more severe hepatitis than their counterparts. 1 The hepatitis D virion consists of the hepatitis D RNA genome, hepatitis D antigen (HDAg), and a lipoprotein envelope containing HBV surface antigen (HBsAg) proteins. 2 Thus, HDV requires HBV in addition to cellular RNA polymerases for replication and cannot infect individuals without the presence of HBsAg which is required for cell entry, virion assembly and export. Since the widespread availability of the hepatitis B vaccine with worldwide implementation of vaccination programs, one would expect a concomitant decrease in HDV alongside HBV. However, the prevalence of HDV appears to be rising and may be attributed to the higher prevalence of HDV infection in individuals with HIV co-infection and intravenous drug users. 3, 4 The global burden of disease is estimated to be 62 to 72 million, affecting nearly 1% of the general population. 4 

Infection with hepatitis D can occur under two circumstances (Error! Reference source not found.). Coinfection occurs when an individual is exposed to both hepatitis B and D viruses simultaneously with a similar presentation to acute HBV infection and potential risk of acute liver failure. Superinfection occurs when an individual with established chronic hepatitis B infection (defined by the presence of hepatitis B surface antigen) is exposed to an acute hepatitis D infection. Whereas superinfection with HDV is more likely to develop into chronic infection, 95% of individuals with HBV-HDV coinfection ultimately have viral clearance. 5 Chronic HDV infection is the most aggressive form of viral hepatitis with greater rates of hepatocellular carcinoma and more rapid progression to cirrhosis compared to HBV mono-infection. [6] [7] [8] [9] Screening for HDV is recommended for individuals with chronic HBV (HBsAg positivity) and

presence of one of more of the following risk factors: 10 but remains to be validated and has not yet been studied for grading lesser degrees of fibrosis.

Thus, liver biopsy is typically still required for accurate grading of inflammation and staging of fibrosis.

Interferon alfa (IFN-α) is currently the only available treatment for chronic HDV infection. The goal of HDV therapy is to achieve viral suppression with sustained clearance of HDV after treatment completion. Thus far, no study has been able to achieve this in the majority of patients treated. 17 The Hep-Net International Delta Hepatitis Intervention Trial (HIDIT), a large multicenter initiative, treated patients with peginterferon α-2a and/or adefovir for 48 weeks of therapy. Six months after treatment completion, 28% of patients treated with interferon alone had continued undetectable HDV RNA with no additional benefit derived in those who also received adefovir and no response in individuals treated with adefovir alone. 18 In the follow-up study HIDIT-II, treating with peginterferon α-2a with or without tenofovir, only 23% of patients had undetectable HDV RNA 24 weeks after completing a 96 week course of therapy with interferon and no additional benefit from concomitant tenofovir therapy. 19 The international societies, including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL), do not provide specific guidelines on indications for chronic HDV treatment. 10, 20, 21 Decision to treat with interferon must be balanced between the suspected degree of inflammation and fibrosis and whether the trajectory of disease warrants the potential side effects from interferon therapy and expected low response rates. Although the presence of HDV typically suppresses HBV replication, 22 treatment with a nucleoside/nucleotide analogue (entecavir or tenofovir) is generally recommended for patients with HBV DNA levels >2,000 IU/mL and all patients with cirrhosis regardless of HBV replication status (Error! Reference source not found.).

The ability to truly achieve sustained virologic response (SVR) in the treatment of HDV remains uncertain given the high rates of late relapse. Follow-up of the HIDIT-1 study participants at a median time of 4.5 years found detectable HDV RNA levels in half of the patients who had met the initial SVR definition with undetectable HDV RNA 24 weeks after treatment. 23 Likelihood of response may be predicted by HDV RNA and HBsAg kinetics during treatment. 24 Earlier decline of HDV RNA levels by more than two log copies/mL and HBsAg less than 1000 IU/mL by week 24

of therapy indicate a higher likelihood of virologic response after treatment completion. 25, 26 Due to the high rates of relapse, ongoing surveillance for HDV RNA is needed, particularly in the setting of transaminase elevation after completion of prior therapy. However, loss of HBsAg after treatment for HDV with IFN is considered a marker of cure for both HBV and HDV.

In patients with chronic HDV infection who are decompensated and unable to tolerate IFN due to its side effects, liver transplantation may be considered. As with all patients with cirrhosis, ongoing screening is needed for esophageal varices and hepatocellular carcinoma. For patients who undergo liver transplantation, HBIG is administered similar to patients with HBV monoinfection which results in clearance of HBsAg and HDV RNA. 27 Given the paucity of treatment options, high relapse rates, and poor side effect profile, there remains a need and ongoing investigation for a treatment option that may be more efficacious.

Novel treatments with promising early data under investigation include myrcludex, an entry inhibitor that blocks both HDV and HBV hepatocyte entry, the prenylation inhibitor lonafarnib, which inhibits farnesyl transfersase a key enzyme required for HDV replication, and pegylated interferon lambda, a type 3 interferon. 28 HEV was subsequently named in 1990 to distinguish it from hepatitis A virus, an additional source of waterborne hepatitis epidemics at the time. 29 There are 4 known HEV genotypes.

Infections with genotypes 1 and 2 are limited to humans and cause disease via consumption of contaminated water. HEV genotypes 3 and 4 cause zoonotic infections with human disease attributed to consumption of raw or undercooked meat, particularly pork and wild game;. 30 Thus, HEV endemic outbreaks are related to genotypes 1 and 2 typically in Asia, Africa, and

Mexico, and sporadic cases due to genotype 3 and 4 have been observed in nations worldwide.

Clinical presentation in acute HEV infection is dependent upon the exposed person's risk factors. The majority of healthy individuals are either asymptomatic or have a self-limited course of acute hepatitis with nonspecific symptoms and spontaneous resolution after four to six weeks. 31 More severe clinical courses are observed in infants, pregnant women, and individuals with excessive alcohol consumption or other chronic pre-existing liver diseases. 30, 32 Mortality from acute HEV genotype 1 and 2 infections in developing countries has been largely attributed to acute liver failure in pregnant women. 33 Additionally, HEV has been recognized as a cause of acute on chronic liver failure worldwide. 34 Chronic HEV, defined by chronic hepatitis with elevated aminotransferase levels and persistent detection of HEV RNA for six months after exposure, is rare in immunocompetent individuals but has been increasingly recognized with genotype 3 HEV infections in immunocompromised hosts, particularly in those with solid organ transplants (SOT), stem cell transplants (SCT), or human immunodeficiency virus (HIV). This is likely due to the impaired and/or insufficient immune T-cell response with an inability to control the virus in the immunocompromised state. 35 

After initial exposure and an incubation period of two to eight weeks, HEV RNA may be detectable in the stool and serum for one to two weeks after onset of symptoms. The diagnostic window is narrow since patients typically present after the peak viremic period has concluded. Anti-HEV IgM is produced early after infection, coinciding with peak ALT levels, and may last four to six months. Anti-HEV IgG is first present at low titers and increases incrementally over time. Thus, patients who present early may only have detectable HEV RNA while many patients may not present until the early viremic period has already subsided. 42 In the immunocompetent host, diagnosis of acute HEV infection may require anti-HEV IgM or HEV

In the immunocompromised host, detection of anti-HEV immunoglobulin is lower and frequently undetectable, so diagnosis often requires testing for HEV RNA by PCR for confirmation. The World Health Organization has developed an international standard for nucleic acid amplification techniques to improve HEV RNA detection and quantification. 43 To increase diagnostic rates of HEV, use of at least two of the three above markers is suggested to increase yield, particularly since accuracy and reliability of anti-HEV immunoglobulin assays differ widely in laboratories and among the particular individuals being tested. 42, 44 Although there are distinct HEV genotypes, the body's immune response and production of anti-HEV IgG antibodies are cross-reactive to all four known genotypes. 45 Liver biopsy in acute HEV infection may show a wide range of features including mixed inflammatory infiltrate, interface hepatitis, cholestasis, and apoptotic bodies, which may have similar overlapping features with other viral hepatitis, autoimmune hepatitis, or drug-induced liver injury. 46 Since most cases of acute HEV are self-limited in immunocompetent hosts, liver biopsy is often not necessary. By contrast, liver biopsy is often obtained before chronic HEV infection is suspected in the immunosuppressed host since unexplained transaminase elevations is the typical presentation with no other clinical symptoms. In those with known infection, liver biopsy may be beneficial for staging of fibrosis given the potential risk for accelerated progression to cirrhosis. HEV RNA may be detected in the liver biopsy specimen and histopathology ranges from minimal inflammation to clinical features suggestive of mild acute cellular rejection. 47 Given the nonspecific findings on histologic examination, HEV RNA should be tested in transplant recipients if a liver biopsy demonstrates chronic hepatitis of uncertain etiology or a nondiagnostic biopsy in setting of persistently abnormal liver chemistries. 48 

The initial step in management of chronic HEV is reduction of immunosuppression if possible, particularly medications with an effect on T cells (i.e. calcineurin inhibitors and mammalian target of rapamycin inhibitors), which has been shown to be a sufficient strategy to allow clearance of the virus in one-third of patients. 49 The optimal immunosuppressive regimen still requires further studies with current recommendations to minimize immunosuppression as much as possible and favoring use of mycophenolate rather than calcineurin or mtor inhibitors. 50 Interferon has been used for treatment of hepatitis B and C, so it has similarly been investigated in use for treatment of chronic HEV. 51 However, its long list of potential side effects including the potential for graft rejection makes it a poor treatment option. Ribavirin is used and tolerated well for treatment of chronic HEV in SOT recipients at a median dose of 600mg daily (8 mg/kg) for three months and longer treatment courses for six to twelve months in those with partial response or relapse after treatment. 52 There is currently one licensed vaccine for hepatitis E (HEV 239, Hecolin) available in China which is derived from 26 KDa protein coded by ORF2 of HEV1. 53

There are eight viruses in the Herpesviridae family that can cause disease in humans including viral hepatitis (Error! Reference source not found.). Initial infection with these viruses are typically self-limited before becoming latent infections with the ability to reactivate when there is an immunocompromised or immunosuppressed state.

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are common infections that cause both oral and genital vesicular lesions. Although immunocompetent individuals can develop disseminated HSV with hepatic involvement, it is more common in immunocompromised states including pregnancy, HIV infection, and use of immunosuppressant medications. HSV hepatitis, more commonly due to HSV-2, is less likely to manifest with characteristic mucocutaneous vesicular lesions and typically presents with fever and acute liver failure (ALF) leading to death or liver transplantation in the majority of cases. 54 Diagnosis should be made with HSV DNA by PCR rather than serologies (HSV IgG or IgM) due to the latter's inaccuracies in acute hepatitis. 55 Liver biopsy may be needed for definitive diagnosis and demonstrates hepatocellular necrosis with intranuclear inclusions and immunostaining for HSV. However, immediate initiation of empiric treatment with intravenous acyclovir is recommended given the severity and potentially rapid progression of disease including death if treatment is delayed. 54

Varicella zoster virus (VZV) is commonly known for causing chickenpox in children at the time of initial infection, and later becoming latent in the dorsal root ganglia with reactivation causing shingles in adults. Transmission occurs via aerosolized nasopharyngeal secretions or direct contact with fluid from vesicular lesions. VZV-associated hepatitis has been rarely reported in the literature but can present similarly to HSV hepatitis. 56 Liver biopsy will typically look similar to HSV hepatitis though diagnosis is made by checking serum VZV PCR. Similar to HSV, treatment with acyclovir is recommended. In immunocompromised hosts, varicella zoster immune globulin may be considered if known exposure occurs. 57 An inactivated zoster vaccine (Shingrix) is now available and recommended for post-transplant and other immunocompromised patients. 58

Epstein-Barr virus (EBV) is a common infection that causes infectious mononucleosis with fevers, pharyngitis, and lymphadenopathy. Over 90% of the population has evidence of prior exposure by 20 years of age. 59 Unlike the other herpes viruses, mild hepatitis with hepatomegaly and transaminase elevations typically occur with EBV infection. However, acute liver failure due to EBV is less common, accounting for one in 500 cases of the Acute Liver Failure Study Group (ALFSG) and may occur in young and immunocompetent individuals, unlike the other herpesviruses that typically only lead to ALF in the immunocompromised. 60 After primary infection, the virus becomes latent in the memory B cells. 61 immunoglobulin G, anti-HDV: hepatitis D antibody, HDAg: hepatitis D antigen α may not be present yet in early infection β present transiently, often not detected χ typically remains persistently elevated δ occurs rarely in superinfection, more common in coinfection

Immunofluorescence detection of new antigenantibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers

Zakim and Boyer's Hepatology: A Textbook of Liver Disease

Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program

Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut

Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome

Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B

A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma

A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma

Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia

Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance

World Health Organization. Hepatitis D (Fact Sheet

Serological response to the hepatitis delta virus in hepatitis D

Anti-HDV IgM as a marker of disease activity in hepatitis delta

First international external quality assessment for hepatitis delta virus RNA quantification in plasma

Noninvasive markers for staging fibrosis in chronic delta hepatitis

Vibration-Controlled Transient Elastography for the Detection of Cirrhosis in Chronic Hepatitis D Infection

Hepatitis delta virus

Peginterferon plus adefovir versus either drug alone for hepatitis delta

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Clinical Practice Guidelines on the management of hepatitis B virus infection

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling

Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response

Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis E virus. Comparison of 'New and Old World' isolates

Hepatitis E: source and route of infection, clinical manifestations and new developments

Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death

Hepatitis E and pregnancy: understanding the pathogenesis

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection

Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants

Rheumatologic manifestations of hepatic diseases

Extrahepatic manifestations of hepatitis E virus

Frequency and prognosis of acute pancreatitis associated with acute hepatitis E: A systematic review

Review of the neurological manifestations of hepatitis E infection

Hepatitis E virus and the kidney in solid-organ transplant patients

Profile of acute infectious markers in sporadic hepatitis E

Standardization of Nucleic Acid Tests: the Approach of the World Health Organization

Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study

Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay

The histology of acute autochthonous hepatitis E virus infection

Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation

Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice

Hepatitis E infection in liver transplant recipients

The impact of hepatitis E in the liver transplant setting

Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b

Ribavirin for chronic hepatitis E virus infection in transplant recipients

The development of a recombinant hepatitis E vaccine HEV 239

Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases

Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure

Varicella hepatitis in the immunocompromised adult: a case report and review of the literature

Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients

Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice

Epstein Barr virus hepatitis

Epstein-Barr virus (EBV) related acute liver failure: a case series from the US Acute Liver Failure Study Group

EBV persistence in memory B cells in vivo

Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients

Posttransplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival

Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys

Cytomegalovirus infection in the normal host

Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Human herpesvirus 6 infections after liver transplantation

Human herpesvirus 6, 7, and 8 in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study

The Role of Emerging and Neglected Viruses in the Etiology of Hepatitis